Schizophrenia: The drug deadlock

Nature

Volumn 468, Issue 7321, 2010, Pages 158-159

  Abbott, Alison ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; NEUROLEPTIC AGENT; PERPHENAZINE;

COGNITION; DELUSION; DRUG INDUSTRY; FOOD AND DRUG ADMINISTRATION; HALLUCINATION; HUMAN; METABOLIC DISORDER; NONHUMAN; NOTE; PRESCRIPTION; PRIORITY JOURNAL; SCHIZOPHRENIA; UNITED STATES;

ANIMALS; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; CLOZAPINE; COGNITION; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; HUMANS; PERPHENAZINE; PSYCHOTIC DISORDERS; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS;

EID: 78149449298     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/468158a     Document Type: Note

References (4)

1. Lieberman, J. A. et al. N. Engl. J. Med. 353, 1209-1223 (2005).
2. Buchanan, R. W. et al. Schizophr. Bull. 31, 5-19 (2005).
3. Kirkpatrick, B., Fenton, W. S., Carpenter, W. T. Jr & Marder, S. R. Schizophr. Bull. 32, 214-219 (2006).
4. Steffanson, H. et al. Nature 455, 232-236 (2008).